



## FDP Foreign Cost Reimbursement Subaward

<b>Federal Awarding Agency:</b> National Institutes of Health (NIH)	
<b>Pass-Through Entity (PTE):</b> Georgetown University	<b>Subrecipient:</b> Institute of Biotechnology of the Czech Academy of Sciences
PTE PI: [REDACTED]	Sub PI: [REDACTED]
PTE Federal Award No: R01CA249248	Subaward No: 425659_AWD7775566-IBCAS
Project Title: Development of selective HDAC6 inhibitors to improve cancer immunotherapy	
Subaward Budget Period: Start: 04/01/2022      End: 01/31/2024	Amount Funded This Action (USD): \$ 30,584.79
Estimated Period of Performance Start: [REDACTED]      End: [REDACTED]	Incrementally Estimated Total (USD): \$ [REDACTED]

### Terms and Conditions

1. PTE hereby awards a cost reimbursable Subaward, (as determined by 2 CFR 200.331), to Subrecipient. The Statement of Work and budget for this Subaward are as shown in Attachment 5. In its performance of Subaward work, Subrecipient shall be an independent entity and not an employee or agent of PTE. No Party has the authority to bind any other Party in contract or to incur any debts or obligations on behalf of any other Party, and no Party (including an employee or other representative of such Party) shall take any action that attempts or purports to bind any other Party in contract or to incur any debt or obligations on behalf of any other Party, without the affected party's prior written approval.
2. Subrecipient shall submit invoices Monthly for allowable costs incurred. All invoices shall be submitted using PTE's standard invoice shown in Attachment 6, and shall include current and cumulative costs (including cost sharing information if applicable), breakdown by major cost category, Subaward number, and certification, as required in 2 CFR 200.415 (a). Invoices that do not reference PTE Subaward number shall be returned to Subrecipient. Invoices and questions concerning invoice receipt or payments shall be directed to the party's Financial Contact, shown in Attachment 3A. Expenditures of Subrecipient shall conform to budget in Attachment 5. All payments will be in U.S. Dollars.
3. A final statement of cumulative costs incurred, including cost sharing, marked "FINAL" must be submitted to PTE's Financial Contact, as shown in Attachment 3A, NO LATER THAN 30 Days after Subaward end date. The final statement of costs shall constitute Subrecipient's final financial report.
4. All payments shall be considered provisional and subject to adjustment within the total estimated cost, in the event such adjustment is necessary as a result of an adverse audit finding against the Subrecipient. Upon the receipt of proper invoices, the PTE agrees to process payments in accordance with this Subaward and 2 CFR 200.305.
5. Matters concerning the technical performance of this Subaward Agreement shall be directed to the appropriate party's Principal Investigator as shown in Attachments 3A and 3B. Technical reports are required as shown in Attachment 4 "Reporting Requirements".
6. Matters concerning the request or negotiation of any changes in the terms, conditions, or amounts cited in this Subaward Agreement and any changes requiring prior approval, shall be directed to the PTE's Administrative Contact, and the Subrecipient's Administrative Contact as shown in Attachments 3A and 3B. Any such change made to this Subaward requires the written approval of each party's Authorized Official, as shown in Attachments 3A and 3B.
7. The PTE may issue non-substantive changes (defined as: documentation of prior approvals, addition of non-competing continuation budget periods/funds and no cost extensions) to the Budget Period(s) and Budget Unilaterally. Unilateral modifications shall be considered valid 14 days after receipt, unless otherwise indicated by Subrecipient. Requests for No Cost Extensions are as shown in Attachment 2.
8. Each Party shall be responsible for its negligent acts or omissions, and the negligent acts or omissions of its employees, officers, or directors, to the extent allowed by law.
9. Either party may terminate this Subaward with 30 days written notice. Notwithstanding, if the Awarding Agency terminates the Federal Award, PTE will terminate in accordance with the Awarding Agency requirements. PTE notice shall be directed to the PTE's Authorized Official Contact and the Subrecipient's notice directed to the Authorized Official Contact, as shown in Attachments 3A and 3B. PTE shall pay Subrecipient for termination costs as allowable under Uniform Guidance, 2 CFR 200, or 45 CFR Part 75 Appendix IX, as applicable.
10. No Party shall be in default by reason of any failure in performance of this Subaward if such failure arises, directly or indirectly, out of causes reasonably beyond the direct control or foreseeability of such Party, including but not limited to, acts of God or of the public enemy, U.S. or foreign governmental acts in either a sovereign or contractual capacity, labor, fire, flood, epidemic and strikes.
11. By signing this Subaward, including the attachments hereto which are hereby incorporated by reference, Subrecipient certifies that it will perform the Statement of Work in accordance with the terms and conditions of this Subaward and the applicable terms of the Federal Award, including the appropriate Research Terms and Conditions ("RTCs") of the Federal Awarding Agency, as referenced in Attachment 2. The parties further agree that they intend this Subaward to comply with all applicable laws, regulations and requirements.

By an Authorized Official of Pass-through Entity:  Name: Melissa Layman      Date: 10/30/2023 Title: Senior Director, JORA	By an Authorized Official of Subrecipient:  Name: Bohdan Schneider      Date: [REDACTED] Title: director
--	---

**Attachment 1**  
**Certifications and Assurances**

Subaward Number:

425659\_AWD7775566-IBCAS

By signing the Subaward, the Authorized Official of Subrecipient certifies, to the best of his/her knowledge and belief, that:

**Certification Regarding Lobbying (2 CFR 200.450)**

No U.S. Federal appropriated funds have been paid or will be paid, by or on behalf of the Subrecipient, to any person for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with the awarding of any U.S. Federal contract, the making of any U.S. Federal grant, the making of any U.S. Federal loan, the entering into of any cooperative agreement, and the extension, continuation, renewal, amendment, or modification of any U.S. Federal contract, grant, loan, or cooperative agreement.

If any funds other than Federal appropriated funds have been paid or will be paid to any person for influencing or intending to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with this Federal contract, grant, loan, or cooperative agreement, the Subrecipient shall complete and submit Standard Form -LLL, "Disclosure Form to Report Lobbying," to the PTE.

This certification is a material representation of fact upon which reliance was placed when this transaction was made or entered into. Submission of this certification is a prerequisite for making or entering into this transaction imposed by 31 U.S.C. 1352. Any person who fails to file the required certification shall be subject to a civil penalty of not less than \$10,000 and not more than \$100,000 for each such failure.

**Debarment, Suspension, and Other Responsibility Matters (2 CFR 200.214 and 2 CFR 180)**

All foreign institutions and international organizations, except for foreign governments or governmental entities, public international organizations, or foreign-government-owned or -controlled entities (in whole or in part) are subject to the Debarment, Suspension and Other Responsibility Matters.



Subrecipient certifies by signing this Subaward that neither it, nor its principals, are presently debarred, suspended, proposed for debarment, declared ineligible or voluntarily excluded from participation in this transaction by any U.S. Federal Department or Agency.

Or



Subrecipient is either a foreign government or governmental entity, public international organization, or foreign-government-owned or -controlled entity (in whole or in part); and it IS NOT subject to the debarment or suspension certification requirement or to debarment or suspension under 45 CFR Part 75.

**Audit and Access to Records**

Subrecipient certifies by signing this Subaward that it complies with the Uniform Guidance, will provide PTE notice of the completion of required audits and any adverse findings which impact this Subaward Agreement as required by parts 200.501- 200.521, and will provide access to records as required by parts 200.337 and 200.338 as applicable.

All financial and related documentation, including but not limited to financial reports, invoices, financial audits, or receipts, shall be provided to PTE in English at Subrecipient's expense.

**RESERVED**

**Use of Name**

Neither party shall use the other party's name, trademarks, or other logos in any publicity, advertising, or news release without the prior written approval of an authorized representative of that party. The parties agree that each party may use factual information regarding the existence and purpose of the relationship that is the subject of this Subaward for legitimate business purposes, to satisfy any reporting and funding obligations, or as required by applicable law or regulation without written permission from the other party. In any such statement, the relationship of the parties shall be accurately and appropriately described.

**Foreign Corrupt Practices**

Subrecipient agrees to use funds in compliance with (1) the U.S. Foreign Corrupt Practices Act; (2) Subrecipient agrees that, under this Subaward, it will not offer, promise, or provide (or authorize the offer, promise, or provision of), directly or indirectly, anything of value to any government official, political party official, political candidate, or employee thereof, or to any other third party, for the purpose of obtaining or retaining business or obtaining any illegal benefit or advantage.

---

**Export Controls**

Each Party is responsible for determining whether its performance is subject to, and in compliance with, U.S. export control laws and regulations (“U.S. Export Controls”), including but not limited to the Export Administration Regulations - EAR (Department of Commerce), the International Traffic in Arms Regulations - ITAR (Department of State), the sanctions programs embodied in regulations administered by the Department of the Treasury’s Office of Foreign Assets Control (OFAC), the U.S. anti-boycott laws and regulations (EAA) and U.S. anti-terrorism financing laws and regulations.



Attachment 8 of this Subaward includes additional applicable terms related to Export Controls.

---

**Prohibition on Certain Telecommunication and Video Surveillance Services or Equipment**

Pursuant to 2 CFR 200.216, Subrecipient will not obligate or expend funds received under this Subaward to: (1) procure or obtain; (2) extend or renew a contract to procure or obtain; or (3) enter into a contract (or extend or renew a contract) to procure or obtain equipment, services, or systems that uses covered telecommunications equipment or services (as described in Public Law 115-232, section 889) as a substantial or essential component of any system, or as a critical technology as part of any system.

---

The Subrecipient shall require that the language of the certifications above in this Attachment 1 be included in the award documents for all subawards at all tiers (including subcontracts, subgrants, and contracts under grants, loans, and cooperative agreements) and that all subrecipients shall certify and disclose accordingly.

## Attachment 2

### Federal Award Terms and Conditions

Subaward Number

425659\_AWD7775566-IBCAS

**Required Data Elements**

The data elements required by Uniform  
Guidance are incorporated in the attached Federal Award.

Awarding Agency Institute (If Applicable)

NATIONAL CANCER INSTITUTE

Federal Award Issue Date FAIN Assistance Listing No.

03/24/23

R01CA249248

93.395

Assistance Listing Program Title (ALPT)

Cancer Treatment Research

Key Personnel Per NOA

**This Subaward Is:**

Research & Development  Subject to FFATA

**General Terms and Conditions**

By signing this Subaward, Subrecipient agrees to the following:

- To abide by the conditions on activities and restrictions on expenditure of federal funds in appropriations acts that are applicable to this Subaward to the extent those restrictions are pertinent. This includes any recent legislation noted on the Federal Awarding Agency's website:

<http://grants.nih.gov/policy/notices.htm>

- 2 CFR 200 and 45 CFR Part 75.

- The Federal Awarding Agency's grants policy guidance, including addenda in effect as of the beginning date of the period of performance or as amended found at:

<http://grants.nih.gov/grants/policy/nihgps/nihgps.pdf>

- Research Terms and Conditions, including any Federal Awarding Agency's Specific Requirements found at:

<https://www.nsf.gov/awards/managing/rtc.jsp>

except for the following :

- No-cost extensions require the written approval of the PTE. Any requests for a no-cost extension shall be directed to the  Contact shown in Attachment 3A, not less than 30 days prior to the desired effective date of the requested change.
  - Any payment mechanisms and financial reporting requirements described in the applicable Federal Awarding Agency Terms and Conditions and Agency-Specific Requirements are replaced with Terms and Conditions (1) through (4) of this Subaward; and
  - Any prior approvals are to be sought from the PTE and not the Federal Awarding Agency.
  - Title to equipment as defined in 2 CFR 200.1 that is purchased or fabricated with research funds or Subrecipient cost sharing funds, as direct costs of the project or program, shall vest in the Subrecipient subject to the conditions specified in 2 CFR 200.313.
  - Prior approval must be sought for a change in Subrecipient PI or change in Key Personnel (defined as listed on the NOA).
- Treatment of program income:

**Special Terms and Conditions:****Data Sharing and Access:**

Subrecipient agrees to comply with the Federal Awarding Agency's data sharing and/or access requirements as reflected in the NOA or the Federal Awarding Agency's standard terms and conditions as referenced in General Terms and Conditions 1-4 above.

**Data Rights:**

Subrecipient grants to PTE the right to use data created in the performance of this Subaward solely for the purpose of and only to the extent required to meet PTE's obligations to the Federal Government under its PTE Federal Award.

**Copyrights:**

to PTE an irrevocable, royalty-free, non-transferable, non-exclusive right and license to use, reproduce, make derivative works, display, and perform publicly any copyrights or copyrighted material (including any computer software and its documentation and/or databases) first developed and delivered under this Subaward solely for the purpose of and only to the extent required to meet PTE's obligations to the Federal Government under its PTE Federal Award.

Subrecipient grants to PTE the right to use any written progress reports and deliverables created under this Subaward solely for the purpose of and only to the extent required to meet PTE's obligations to the Federal Government under its Federal Award.

**Promoting Objectivity in Research (COI):**

Subrecipient must designate herein which entity's Financial Conflicts of Interest policy (COI) will apply:

If applying its own COI policy, by execution of this Subaward, Subrecipient certifies that its policy complies with the requirements of the relevant Federal Awarding Agency as identified herein:

Subrecipient shall report any financial conflict of interest to PTE's Administrative Representative or COI contact, as designated on Attachment 3A. Any financial conflicts of interest identified shall, when applicable, subsequently be reported to Federal Awarding Agency. Such report shall be made before expenditure of funds authorized in this Subaward and within 45 days of any subsequently identified COI.

**Governing Language:**

In the event that a translation of this Subaward is prepared and signed by the parties, and a conflict arises between the English version and other language version, this English language version shall be the official version and shall govern and control.

---

**Governing Law:**

The Parties acknowledge that PTE is subject to the laws of the United States. The parties hereby agree that nothing in this Subaward or any of its attachments or references shall be deemed to require either Party to breach any mandatory statutory law under which each Party is operating.

---

**Patents:**

Pursuant to Public Law 96-517, as amended by Public law 98-620, title to any invention or discovery made or conceived under this Subaward shall vest in the Subrecipient. Subrecipient shall promptly notify PTE as shown in Attachment 4 hereto.

Subrecipient hereby grants to PTE a royalty-free, non-exclusive license for research purposes to any Subrecipient invention or discovery under this Subaward.

---

**Second Tier Subawards:**

Subrecipient may not issue any subawards under this Subaward without the express prior written consent of PTE. In the event that such consent is granted, all assurances, certifications, and terms included in this Subaward shall be flowed down to the second tier subaward.

---

**Disputes:**

The Parties shall attempt to resolve disputes through good faith negotiations. Any dispute arising under, or related to, this Subaward shall be resolved to the maximum possible extent through informal dispute resolution. Unresolved issues shall be arbitrated in accordance with the International Arbitration Rules of the American Arbitration Association.  
Arbitration Association.

---

**Additional Terms**

1. ANTI-TERRORIST COMPLIANCE: Subrecipient hereby agrees that all funds will be used in compliance with all applicable United States anti-terrorist financing and asset control laws, regulations, rules and executive orders.
2. INSURANCE REQUIREMENTS: Subrecipient shall maintain, at its own cost and expense, sufficient liability insurance or self-insurance to cover Subrecipient's obligations under this Agreement. Upon request, Subrecipient shall provide a certificate of insurance to University. If applicable, Subrecipient shall maintain cyber liability, network liability, data breach or similar privacy liability insurance coverage in the amount sufficient to cover its obligations under this Agreement. Such insurance shall provide coverage on a worldwide basis. If applicable, Subrecipient shall maintain professional liability insurance coverage in the amount sufficient to cover its obligations under this Agreement.
3. EXPORT CONTROLS: It is understood that University is subject to United States laws and regulations controlling the export of technical data, computer software, laboratory prototypes and other commodities, and that its obligations hereunder are contingent on compliance with applicable U.S. export laws and regulations (including the Arms Export Control Act, as amended, and the Export Administration Act of 1979). The transfer of any such Technology and Items and the entering into and provision of such Transactions and Services that are subject to Restrictions may require a license or authorization from the cognizant agency of the United States Government, and/or may require written assurances by the receiving party that it shall not re-export such Technology and Items to certain foreign destinations and/or to certain recipients without prior approval of the cognizant government agency, and/or may require that the involved individuals and entities will comply with conditions on Transactions and Services. While University agrees to cooperate in securing any license which the cognizant agency deems necessary in connection with this Agreement, University cannot guarantee that such licenses will be granted.
4. As per NIH Grants Policy Statement, section 15.2, 15.2.1  
Note: All current requirements remain in place, with the addition of:  
For foreign subrecipients, a provision requiring the foreign subrecipient to provide access to copies of all lab notebooks, all data, and all documentation that supports the research outcomes as described in the progress report, to the primary recipient with a frequency of no less than once per year, in alignment with the timing requirements for Research Performance Progress Report submission. Such access may be entirely electronic.

---

**Work Involving Human or Vertebrate Animals** (Select Applicable Options)

No Human or Vertebrate Animals

This section left intentionally blank.

---

**Human Subjects Data** (Select One)

This section left intentionally blank

---

**NIH Terms and Conditions**

The Clinical Trial Indicator in Section IV of the PTE's NOA is stated as:

**Multiple PIs (MPI)**

**Certificate of Confidentiality:**

The Parties agree that this research funded in whole or in part by the National Institutes of Health ("NIH"), is subject to NIH Policy NOT-OD-17-109 (the "Policy") and therefore is deemed under the Policy to be issued a Certificate of Confidentiality ("Certificate") should the conditions outlined within the Policy apply. Accordingly, the subrecipients who collect or receive identifiable, sensitive information are is required to adhere to the Policy and protect the privacy of individuals who are subjects of such research in accordance with the Policy and subsection 301(d) of the Public Health Service Act (the "PHS Act").

---

**Attachment 3A**  
**Pass-Through Entity (PTE) Contacts**

Subaward Number:  
425659\_AWD7775566-IE

**PTE Information**

Entity UEI Name:

Legal Address:

Website:

**PTE Contacts**

Central Email:

Principal Investigator Name:

Email:  Telephone Number:

Administrative Contact Name:

Email:  Telephone Number:

COI Contact email (if different to above):

Financial Contact Name:

Email:  Telephone Number:

Email invoices?  Yes  No Invoice email (if different):

Authorized Official Name:

Email:  Telephone Number:

**PI Address:**

4000 Reservoir Road, NW Washington, DC 20007 United States of America

**Administrative Address:**

Office of Sponsored Research  
Building D, Room 237  
4000 Reservoir Rd, NW  
Washington, DC 20007

**Invoice Address:**

Send electronically to subaward@georgetown.edu  
  
Include Subaward Number and Supplier ID: SUP-0076933

# Attachment 3B

## Subrecipient Contacts

Subaward Number:

425659\_AWD7775566-IBCAS

### Subrecipient Information for **FFATA** reporting

Entity's UEI Name:

EIN No.:  Institution Type:

UEI:  Currently registered in SAM.gov:  Yes  No

Exempt from reporting executive compensation:  Yes  No *(if no, complete 3Bpg2)*

Parent UEI:  *This section for U.S. Entities:* Zip Code [Look-up](#)

Place of Performance Address Congressional District:  Zip Code+4:

### Subrecipient Contacts

Central Email:

Website:

Principal Investigator Name:

Email:  Telephone Number:

Administrative Contact Name:

Email:  Telephone Number:

Financial Contact Name:

Email:  Telephone Number:

Invoice Email:

Authorized Official Name:

Email:  Telephone Number:

### Legal Address:

### Administrative Address:

### Payment Address:



**Attachment 3B-2**  
**Highest Compensated Officers**

Subaward Number:

425659\_AWD7775566-IBCAS

**Subrecipient:**

Institution Name:

PI Name:

**Highest Compensated Officers**

The names and total compensation of the five most highly compensated officers of the entity(ies) must be listed if the entity in the preceding fiscal year received 80 percent or more of its annual gross revenues in Federal awards; and \$25,000,000 or more in annual gross revenues from Federal awards; and the public does not have access to this information about the compensation of the senior executives of the entity through periodic reports filed under section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. §§ 78m(a), 78o(d)) or section 6104 of the Internal Revenue Code of 1986. See FFATA § 2(b)(1) Internal Revenue Code of 1986.

Officer 1 Name:

Officer 1 Compensation:

Officer 2 Name:

Officer 2 Compensation:

Officer 3 Name:

Officer 3 Compensation:

Officer 4 Name:

Officer 4 Compensation:

Officer 5 Name:

Officer 5 Compensation:

## Attachment 4

### Reporting and Prior Approval Terms

Subaward Number:

425659\_AWD7775566-IBCAS

Subrecipient agrees to submit the following reports (PTE contacts are identified in Attachment 3A):

#### Technical Reports:

- Monthly technical/progress reports will be submitted to the PTE's  within  days of the end of the month.
- Quarterly technical/progress reports will be submitted within 30 days after the end of each project quarter to the PTE's .
- Annual technical / progress reports will be submitted  days prior to the end of each budget period to the PTE's . Such report shall also include a detailed budget for the next Budget Period, updated other support for key personnel, certification of appropriate education in the conduct of human subject research of any new key personnel, and annual IRB or IACUC approval, if applicable.
- A Final technical/progress report will be submitted to the PTE's  within  days of the end of the Project Period or after termination of this award, whichever comes first.
- Technical/progress reports on the project as may be required by PTE's  in order for the PTE to satisfy its reporting obligations to the Federal Awarding Agency.

#### Prior Approvals:

Carryover:

#### Other Reports:

- In accordance with 37 CFR 401.14, Subrecipient agrees to notify both the Federal Awarding Agency via iEdison and PTE's  within 60 days after Subrecipient's inventor discloses invention(s) in writing to Subrecipient's personnel responsible for patent matters. The Subrecipient will submit a final invention report using Federal Awarding Agency specific forms to the PTE's  within 60 days of the end of the Project Period to be included as part of the PTE's final invention report to the Federal Awarding Agency.  
A negative report is required:
- Property Inventory Report (only when required by Federal Awarding Agency), specific requirements below.
- Each invoice must be accompanied by a brief technical report, and: (i) be sequentially numbered; (ii) indicate the date(s) of performance by the Subrecipient; (iii) state the Purchase Order number, the title of the project and the name of the PTE Principal Investigator; (iv) itemize costs in detail, in accordance with the Subaward budget; (v) include both current costs and cumulative costs; (vi) include the Subrecipient certification, with authorized official's signature, that costs are appropriate and accurate and that payment has not yet been received; and (vii) be supported by a general ledger report originating directly from the Subrecipient's financial record keeping system. PTE may request supporting documentation in certain categories prior to or subsequent to approving the invoice. Supporting documentation includes, but is not limited to, travel receipts, purchase orders, invoices for services or supplies, or time records, Property Inventory Report; frequency, type, and submission instructions listed here and only to be used when required by PTE Federal Award.

**Other Special Reporting Requirements:**

A large, empty rectangular box with a thin black border, occupying most of the page below the section header. It is intended for the user to provide details regarding other special reporting requirements.

**Attachment 5**  
**Statement of Work, Cost Sharing, Indirects & Budget**

Subaward Number:

425659\_AWD7775566-IBCAS

**Statement of Work**

Below  Attached,  pages

If award is FFATA eligible and SOW exceeds 4000 characters, include a *Subrecipient Federal Award Project Description*

**Budget Information**

<b>Indirect Information</b> Indirect Cost Rate (IDC) Applied <input style="width: 50px; text-align: center;" type="text" value="8"/> % Rate Type: <input style="width: 200px;" type="text" value="Modified Total Direct Costs"/>	<b>Cost Sharing</b> <input style="width: 100px;" type="text" value="No"/> If Yes, include Amount: \$ <input style="width: 80px;" type="text"/>
---	---

**Budget Details**  Below  Attached,  pages

The Budget is for POP 4/1/2022 - 01/31/2024 as follows:


1. 04/01/2022-01/31/2023 - \$12,086.11
2. 02/01/2023-01/31/2024 - \$18,498.68

**Budget Totals**

Direct Costs	\$	<input style="width: 100%;" type="text" value="28,319.25"/>
Indirect Costs	\$	<input style="width: 100%;" type="text" value="2,265.54"/>
Total Costs	\$	<input style="width: 100%;" type="text" value="30,584.79"/>

*All amounts are in United States Dollars*

ATTACHMENT 5 (Cont)  
Scope of Work and Budget Justification



**April' 22 - January' 23**

salary	147,437.00 Kč	\$6,857.53
fringe benefits	52,780.00 Kč	\$2,454.88
material	40,386.17 Kč	\$1,878.43
indirect costs - 8 %	19,248.25 Kč	\$895.27
<b>subtotal</b>	<b>259,851.42 Kč</b>	<b>\$12,086.11</b>

**February' 23 - January' 24**

salary	131,976.00 Kč	\$6,138.42
fringe benefits	47,246.40 Kč	\$2,197.51
material	189,038.36 Kč	\$8,792.48
indirect costs - 8 %	29,460.86 Kč	\$1,370.27
<b>subtotal</b>	<b>397,721.62 Kč</b>	<b>\$18,498.68</b>

<b>Total</b>	<b>657,573.04 Kč</b>	<b>\$30,584.79</b>
--------------	----------------------	--------------------

**Attachment 7**

**Notice of Award (NOA), DUA, and any additional documents**

- The following pages include the NOA and if applicable any additional documentation referenced throughout this Subaward.
- Not incorporating the NOA or any additional documentation to this Subaward.



**Recipient Information**

**1. Recipient Name**

GEORGETOWN UNIVERSITY  
MAIN CAMPUS

WASHINGTON, 20057

**2. Congressional District of Recipient**

98

**3. Payment System Identifier (ID)**

1530196603A1

**4. Employer Identification Number (EIN)**

530196603

**5. Data Universal Numbering System (DUNS)**

049515844

**6. Recipient's Unique Entity Identifier**

TF2CMKY1HMX9

**7. Project Director or Principal Investigator**

[REDACTED]

**8. Authorized Official**

[REDACTED]

**Federal Agency Information**

**9. Awarding Agency Contact Information**

[REDACTED]

NATIONAL CANCER INSTITUTE

[REDACTED]

**10. Program Official Contact Information**

[REDACTED]

NATIONAL CANCER INSTITUTE

[REDACTED]

**Federal Award Information**

**11. Award Number**

7R01CA249248-03

**12. Unique Federal Award Identification Number (FAIN)**

R01CA249248

**13. Statutory Authority**

42 USC 241 42 CFR 52

**14. Federal Award Project Title**

Development of selective HDAC6 inhibitors to improve cancer immunotherapy

**15. Assistance Listing Number**

93.395

**16. Assistance Listing Program Title**

Cancer Treatment Research

**17. Award Action Type**

Change of Recipient Organization

**18. Is the Award R&D?**

Yes

**Summary Federal Award Financial Information**

**19. Budget Period Start Date** 04/01/2022 – **End Date** 01/31/2023

**20. Total Amount of Federal Funds Obligated by this Action**

20 a. Direct Cost Amount

20 b. Indirect Cost Amount

**21. Authorized Carryover**

**22. Offset**

**23. Total Amount of Federal Funds Obligated this budget period**

**24. Total Approved Cost Sharing or Matching, where applicable**

**25. Total Federal and Non-Federal Approved this Budget Period**

**26. Project Period Start Date** 02/01/2021 – **End Date** 01/31/2026

**27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period**

**28. Authorized Treatment of Program Income**

Additional Costs

**29. Grants Management Officer - Signature**

[REDACTED]

**30. Remarks**

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.



## Notice of Award



RESEARCH  
Department of Health and Human Services  
National Institutes of Health



NATIONAL CANCER INSTITUTE

---

**SECTION I – AWARD DATA – 7R01CA249248-03****Principal Investigator(s):**

[REDACTED]  
[REDACTED]  
[REDACTED]

**Award e-mailed to:** brightt@georgetown.edu

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of [REDACTED] (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to GEORGETOWN UNIVERSITY in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA249248. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

[REDACTED]

Grants Management Officer  
NATIONAL CANCER INSTITUTE

Additional information follows

**Cumulative Award Calculations for this Budget Period (U.S. Dollars)**

- Salaries and Wages
- Fringe Benefits
- Personnel Costs (Subtotal)
- Materials & Supplies
- Travel
- Other
- Subawards/Consortium/Contractual Costs
- Publication Costs

- Federal Direct Costs
- Federal F&A Costs
- Approved Budget
- Total Amount of Federal Funds Authorized (Federal Share)
- TOTAL FEDERAL AWARD AMOUNT**

**AMOUNT OF THIS ACTION (FEDERAL SHARE)**



SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
3		
4		
5		
6		

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**Fiscal Information:**

Payment System Identifier: 1530196603A1  
 Document Number: RCA249248B  
 PMS Account Type: P (Subaccount)  
 Fiscal Year: 2022

IC	CAN	2022	2023	2024	2025
CA	8479567				

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**NIH Administrative Data:**

PCC: SVBP / OC: 41025 / Released: [REDACTED] 02/14/2023  
 Award Processed: 02/15/2023 12:14:40 AM

**SECTION II – PAYMENT/HOTLINE INFORMATION – 7R01CA249248-03**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

---

**SECTION III – STANDARD TERMS AND CONDITIONS – 7R01CA249248-03**

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

**Research and Development (R&D):** All awards issued by the National Institutes of Health (NIH) meet the definition of “Research and Development” at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase VII Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01CA249248. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

Recipients must administer the project in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age, and comply with applicable conscience protections. The recipient will comply with applicable laws that prohibit discrimination on the basis of sex, which includes discrimination on the basis of gender identity, sexual orientation, and pregnancy. Compliance with these laws requires taking reasonable steps to provide meaningful access to persons with limited English proficiency and providing programs that are accessible to and usable by persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See <https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html> and <https://www.hhs.gov/>.

- Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals, see <https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html> and <https://www.lep.gov>.
- For information on an institution's specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and to provide effective communication, see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>.
- HHS funded health and education programs must be administered in an environment free of sexual harassment; see <https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html>. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see <https://grants.nih.gov/grants/policy/harassment.htm>.
- For guidance on administering programs in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws, see <https://www.hhs.gov/conscience/conscience-protections/index.html> and <https://www.hhs.gov/conscience/religious-freedom/index.html>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

**Treatment of Program Income:**

Additional Costs

---

**SECTION IV – CA SPECIFIC AWARD CONDITIONS – 7R01CA249248-03**

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

**INFORMATION:** This award is issued using FY 2022 funds released by the early termination of 5R01CA249248-02 at George Washington University on 3/31/22. If the unobligated balance from the 02-year has been overestimated, it may be necessary to reduce this award.

**INFORMATION:** This award is issued at a total cost level of [REDACTED] using fiscal year 2022 funds released as a result of the early termination of 5R01CA249248-02 at George Washington University. Additional facilities and administrative costs not to exceed \$70,009 will be provided in a revised award only if fiscal year 2022 funds become available.

**INFORMATION:** This award reflects National Cancer Institute approval to charge allowable pre-award costs beyond the 90-day limit included in National Institutes of Health Grants Policy. Allowable pre-award costs may be charged to this award beginning on 4/1/22, in accordance with the conditions outlined in the [NIH Grants Policy Statement](#).

**INFORMATION:** This award includes funds awarded for consortium activity. Consortia are to be established and administered as described in the [NIH Grants Policy Statement \(NIH GPS\)](#).

**INFORMATION:** This award is contingent upon the following: No individual who receives salary support from this project may receive compensation for more than 12 calendar months (i.e., 100%) total effort from all of their sources of support.

**INFORMATION:** As described in [NOT-CA-21-096](#), Principal Investigators (PIs), including Project Leaders on multi-project grants, will be required to commit a minimum level of effort to be eligible for NCI funding through R01, U01, P01, and R21 grant mechanisms. This award has been issued based on the PI/MPI and Project Leaders (if applicable) devoting the NCI required minimum effort. Any reduction below the approved level of effort requires NCI prior approval.

**INFORMATION:** To help expedite NCI's response to prior approval requests, please submit requests for change of PD/PI, carryover or no cost extensions electronically through the eRA Commons at [Prior Approval Module](#). All other post award requests should be submitted to [NCIGrantsPostAward@nih.gov](mailto:NCIGrantsPostAward@nih.gov). All electronically submitted requests will be tracked and forwarded to the appropriate Grants Management personnel.

**INFORMATION:** This award, including the budget and the budget period, has been discussed between [REDACTED] of the National Cancer Institute and [REDACTED] on 2/7/23.

**SPREADSHEET SUMMARY**

**AWARD NUMBER:** 7R01CA249248-03

**INSTITUTION: GEORGETOWN UNIVERSITY**

Budget	Year 3	Year 4	Year 5	Year 6
Salaries and Wages				
Fringe Benefits				
Personnel Costs (Subtotal)				
Materials & Supplies				
Travel				
Other				
Subawards/Consortium/Contractual Costs				
Publication Costs				
TOTAL FEDERAL DC				
TOTAL FEDERAL F&A				
TOTAL COST				
Facilities and Administrative Costs				
F&A Cost Rate 1				
F&A Cost Base 1				
F&A Costs 1				



**Recipient Information**

- 1. Recipient Name**  
GEORGETOWN UNIVERSITY  
MAIN CAMPUS  
  
WASHINGTON, DC 20057
- 2. Congressional District of Recipient**  
98
- 3. Payment System Identifier (ID)**  
1530196603A1
- 4. Employer Identification Number (EIN)**  
530196603
- 5. Data Universal Numbering System (DUNS)**  
049515844
- 6. Recipient's Unique Entity Identifier**  
TF2CMKY1HMX9
- 7. Project Director or Principal Investigator**  
[REDACTED]  
Associate Professor  
[REDACTED]  
[REDACTED]
- 8. Authorized Official**  
[REDACTED]  
[REDACTED]  
[REDACTED]

**Federal Agency Information**

- 9. Awarding Agency Contact Information**  
[REDACTED]  
  
NATIONAL CANCER INSTITUTE  
[REDACTED]  
[REDACTED]
- 10. Program Official Contact Information**  
[REDACTED]  
  
NATIONAL CANCER INSTITUTE  
[REDACTED]  
[REDACTED]

**Federal Award Information**

- 11. Award Number**  
5R01CA249248-04
- 12. Unique Federal Award Identification Number (FAIN)**  
R01CA249248
- 13. Statutory Authority**  
42 USC 241 42 CFR 52
- 14. Federal Award Project Title**  
Development of selective HDAC6 inhibitors to improve cancer immunotherapy
- 15. Assistance Listing Number**  
93.395
- 16. Assistance Listing Program Title**  
Cancer Treatment Research
- 17. Award Action Type**  
Non-Competing Continuation
- 18. Is the Award R&D?**  
Yes

**Summary Federal Award Financial Information**

- 19. Budget Period Start Date** 02/01/2023 – **End Date** 01/31/2024
- 20. Total Amount of Federal Funds Obligated by this Action**  
20 a. Direct Cost Amount  
20 b. Indirect Cost Amount
- 21. Authorized Carryover**
- 22. Offset**
- 23. Total Amount of Federal Funds Obligated this budget period**
- 24. Total Approved Cost Sharing or Matching, where applicable**
- 25. Total Federal and Non-Federal Approved this Budget Period**  
-----
- 26. Project Period Start Date** 02/01/2021 – **End Date** 01/31/2026
- 27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period**

- 28. Authorized Treatment of Program Income**  
Additional Costs
- 29. Grants Management Officer - Signature**  
[REDACTED]

**30. Remarks**

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

## Notice of Award



RESEARCH  
Department of Health and Human Services  
National Institutes of Health



NATIONAL CANCER INSTITUTE

---

**SECTION I – AWARD DATA – 5R01CA249248-04****Principal Investigator(s):**

[REDACTED]  
[REDACTED]  
[REDACTED]

**Award e-mailed to:** brightt@georgetown.edu

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of [REDACTED] (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to GEORGETOWN UNIVERSITY in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA249248. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

[REDACTED]

Grants Management Officer  
NATIONAL CANCER INSTITUTE

Additional information follows




**Cumulative Award Calculations for this Budget Period (U.S. Dollars)**

Salaries and Wages  
 Fringe Benefits  
 Personnel Costs (Subtotal)  
 Materials & Supplies  
 Travel  
 Other  
 Subawards/Consortium/Contractual Costs  
 Publication Costs

Federal Direct Costs  
 Federal F&A Costs  
 Approved Budget  
 Total Amount of Federal Funds Authorized (Federal Share)  
**TOTAL FEDERAL AWARD AMOUNT**

**AMOUNT OF THIS ACTION (FEDERAL SHARE)**



SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
4		
5		
6		

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**Fiscal Information:**

Payment System Identifier: 1530196603A1  
 Document Number: RCA249248B  
 PMS Account Type: P (Subaccount)  
 Fiscal Year: 2023

IC	CAN	2023	2024	2025
CA	8479567			

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**NIH Administrative Data:**

PCC: SVBP / OC: 41025 / Released: [REDACTED] 03/23/2023  
 Award Processed: 03/24/2023 12:05:29 AM

**SECTION II – PAYMENT/HOTLINE INFORMATION – 5R01CA249248-04**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

**SECTION III – STANDARD TERMS AND CONDITIONS – 5R01CA249248-04**

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

**Research and Development (R&D):** All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase VII Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01CA249248. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

Recipients must administer the project in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age, and comply with applicable conscience protections. The recipient will comply with applicable laws that prohibit discrimination on the

basis of sex, which includes discrimination on the basis of gender identity, sexual orientation, and pregnancy. Compliance with these laws requires taking reasonable steps to provide meaningful access to persons with limited English proficiency and providing programs that are accessible to and usable by persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See <https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html> and <https://www.hhs.gov/>.

- Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals, see <https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html> and <https://www.lep.gov>.
- For information on an institution's specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and to provide effective communication, see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>.
- HHS funded health and education programs must be administered in an environment free of sexual harassment; see <https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html>. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see <https://grants.nih.gov/grants/policy/harassment.htm>.
- For guidance on administering programs in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws, see <https://www.hhs.gov/conscience/conscience-protections/index.html> and <https://www.hhs.gov/conscience/religious-freedom/index.html>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

**Treatment of Program Income:**

Additional Costs

---

**SECTION IV – CA SPECIFIC AWARD CONDITIONS – 5R01CA249248-04**

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

**INFORMATION:** In accordance with the National Cancer Institute's (NCI's) current fiscal year (FY) funding policies, this non-competing award has been issued at 98% of the level indicated for this budget period on the prior Notice of Grant Award.

**REQUIREMENT:** NCI has determined this award includes foreign components.

All foreign components must be reported in G9 of RPPR, and the dollar amount spent in foreign countries (if applicable) must be reported in E4 in the RPPR.

**INFORMATION:** This award is contingent upon the following: No individual who receives salary support from this project may receive compensation for more than 12 calendar months (i.e., 100%) total effort from all of their sources of support.

**INFORMATION:** To help expedite NCI's response to prior approval requests, please submit requests for change of PD/PI, carryover or no cost extensions electronically through the eRA Commons at [Prior Approval Module](#). All other post award requests should be submitted to [NCIGrantsPostAward@nih.gov](mailto:NCIGrantsPostAward@nih.gov). All electronically submitted requests will be tracked and forwarded to the appropriate Grants Management personnel.

**SPREADSHEET SUMMARY**

**AWARD NUMBER:** 5R01CA249248-04

**INSTITUTION:** GEORGETOWN UNIVERSITY

Budget	Year 4	Year 5	Year 6			
Salaries and Wages						
Fringe Benefits						
Personnel Costs (Subtotal)						
Materials & Supplies						
Travel						
Other						
Subawards/Consortium/Contractual Costs						
Publication Costs						
TOTAL FEDERAL DC						
TOTAL FEDERAL F&A						
TOTAL COST						
Facilities and Administrative Costs						
F&A Cost Rate 1						
F&A Cost Base 1						
F&A Costs 1						

**Attachment 8**

Research Subaward  
Export Controls

*List any Export Controls that apply to this Subaward here. Leave this blank if not applicable.*

**Subgrantee agrees to comply with all applicable United States laws and regulations controlling the export of goods, technology, software and services, including the International Traffic in Arms Regulations, the Export Administration Regulations, and the sanctions regulations administered by the Office of Foreign Asset Controls of the U.S. Department of the Treasury. The transfer of goods, technology, software, and services, including technical data to a foreign person, either inside or outside the U.S., may require a license from a U.S. government agency, unless an exemption is available. Subgrantee acknowledges that it will take all necessary steps to comply with export control regulations, including obtaining export licenses if necessary.**